arrow_back Back to Home
InGoodHands
Talk to Expert
verified ✓ Clinically Verified against FDA Titration Protocols | Updated for 2026

GLP-1 Weight Loss Calculator: Project Your Personalized Timeline

Estimate your personalized weight loss timeline with Semaglutide or Tirzepatide using our data-driven calculator. Grounded in clinical trials, reviewed by our medical team.

GLP-1 receptor agonists — including Semaglutide (marketed as Ozempic and Wegovy) and Tirzepatide (Mounjaro) — represent a breakthrough in evidence-based obesity management. In landmark clinical trials, patients achieved sustained body weight reductions of 14.9% with Semaglutide (STEP-1 trial, 68 weeks) and up to 22.5% with Tirzepatide (SURMOUNT-1 trial, 72 weeks), fundamentally reshaping how physicians approach chronic weight management.

This calculator uses a non-linear decay model calibrated against these peer-reviewed trial datasets to project your personalized weight loss trajectory. Enter your current weight, height, age, and preferred medication to generate a week-by-week timeline — including estimated milestone dates, daily calorie and protein targets for muscle preservation, and your projected BMI classification. Designed specifically for patients in India, the tool incorporates Endocrine Society of India (ESI 2025) BMI thresholds that account for the unique metabolic profiles of South Asian populations.

All projections are population-level estimates for educational purposes. Individual results require clinical evaluation by a licensed physician. Read our full medical disclaimer.

tune 1. Personalize Your Trajectory

Adjust the sliders or values to reflect your current physical profile.

Height Input Mode
monitor_weight kg
Range: 35 - 300 kg
adjust kg
Must be less than current weight
height cm
Used to calculate starting BMI
cake yrs
Must be 18 or older to enroll
Results Projection
Expected Loss (48 Wks) —
Timeline to Target
—
Recommended Daily Targets (Muscle Preservation)
Calories —
Protein —
Carbs —
Fats —
💡 Adequate protein intake is critical to preserve lean muscle tissue during rapid GLP-1 weight reduction.
Calculated Starting BMI: — Loading...
Target Weight Feasibility

Weight Projection Timeline Weeks 0 to 48

assignment Your Personalized Weight Loss Plan

Based on your goals, you'll need approximately — weeks to lose — kg and reach your target weight of — kg using —.

📋 Your Success Checklist
✅
Moderate Calorie Deficit Reduce daily intake by 500-750 calories
✅
Daily Protein Target Consume —g of protein daily
✅
Resistance Training Complete 2-3 strength workouts per week
✅
Daily Hydration Drink — liters of water daily

medical_services 2. Clinical Program Details

If you qualify and are interested, provide your details to request clinical review or schedule your medical consultation.

person
+91
phone
InGoodHands Clinical Protocol Summary
medical_information Obesity Expert Voice Call Consultation: A 30-minute comprehensive review of your clinical history and metabolic baseline (₹49 consult fee).
lab_research Diagnostic Blood Panel: Analysis of thyroid (TSH), blood sugar (HbA1c), liver, and kidney health markers to confirm candidacy.
monitoring Precision Dose Titration: Gradual titration schedules monitored weekly to manage side effects and adapt to lowest effective doses.
fitness_center Muscle Mass Protection: Dedicated metabolic tracking and nutrition frameworks to preserve lean muscle tissue.
Update your inputs to verify clinical eligibility criteria.

🔒 Your health history is fully private and evaluated only under strict medical supervision guidelines.

shield_with_heart
Medical & Clinical Disclaimer

The calculations and timelines generated by this calculator are population-level statistical estimates intended purely for educational and informational purposes. They do not constitute medical advice, diagnosis, or a treatment guarantee.

GLP-1 receptor agonists are prescription-only therapies requiring physician consultation, diagnostic lab evaluations, and continuous clinical oversight.

The Clinical Trial Evidence Behind Our Projections

To ensure the highest standard of health literacy and scientific accuracy, our computational models are calibrated against peer-reviewed data from the world's most rigorous anti-obesity pharmaceutical trials.

The STEP-1 Trial — Semaglutide Breakthrough

Published in The New England Journal of Medicine, the landmark STEP-1 clinical trial evaluated the long-term efficacy of once-weekly Semaglutide. Over a 68-week timeline, adult participants tracking a high-dose maintenance protocol achieved an average total body weight reduction of 14.9%. The trial highlighted that the most rapid velocity of weight loss occurs during the primary 24-to-36-week titration phases before stabilizing into a sustained maintenance window Wilding et al., 2021, PMID: 33567185 open_in_new.

The SURMOUNT-1 Trial — Tirzepatide Efficacy

For individuals utilizing dual GIP/GLP-1 receptor agonists, the SURMOUNT-1 trial demonstrated unprecedented clinical outcomes. Participants escalating to a 15 mg weekly maintenance dose recorded an average body weight reduction of 22.5% over 72 weeks Jastreboff et al., 2022, PMID: 35658024 open_in_new. This dual-pathway mechanism targets both gut satiety receptors and metabolic efficiency, bringing outcomes remarkably close to metabolic surgery profiles.

GLP-1 Clinical Benchmark Summary
Medication Pathway Average Weight Loss % Standard Titration Window
Semaglutide ~14.9% of body weight 16 to 20 Weeks
Tirzepatide ~22.5% of body weight 20 to 24 Weeks
FAQ & Science

Frequently Asked Questions About GLP-1 Weight Management

Our algorithm utilizes a dynamic decay function modeled after standard clinical trial pathways. It recognizes that weight reduction is non-linear. The velocity starts steady during early titration, accelerates during mid-dose adjustments, and smoothly tapers as your body approaches its biological set-point. Your height and current weight are used to establish your baseline Body Mass Index (BMI) to ensure realistic parameters.
We firmly prioritize safety, metabolic health, and patient comfort. Gastrointestinal side effects—such as mild nausea or changes in digestion—typically occur when a dosage is escalated too quickly. InGoodHands builds customized, slow titration roadmaps. By allowing your endocrine system to comfortably adapt to lowest-effective baseline doses, we achieve optimal fat loss while preserving your daily quality of life.
Long-term data, including the STEP-1 trial extension study, confirms that individuals can regain up to two-thirds of their lost weight within a year of stopping medication abruptly if metabolic adaptations are ignored Wilding et al., 2022, PMID: 35441470 open_in_new.

At InGoodHands, our medical team continuously works on a transition plan. We combine medical management with strict macro-nutrient tracking, functional strength guidelines to protect lean mass, and a gradual step-down maintenance strategy to fundamentally reset your biological weight set-point.
Medical weight management requires a rigorous baseline health check. Because our medical review team personally evaluates your health markers, a comprehensive diagnostic blood panel is mandatory. This profile ensures we evaluate your thyroid health, HbA1c levels, renal functions, and metabolic baselines to confirm you are an ideal, safe candidate for the program.
In clinical trials, Semaglutide (a single GLP-1 receptor agonist) achieved an average body weight reduction of ~14.9% over 68 weeks. Tirzepatide (a dual GIP/GLP-1 receptor agonist) achieved higher average weight loss of up to 22.5% over 72 weeks due to dual receptor activation.
South Asians present a unique 'thin-fat phenotype' with higher visceral fat and metabolic risk at lower BMIs. The calculator incorporates Endocrine Society of India (ESI 2025) benchmarks to adjust realistic weight loss expectations and health risk markers.
Without proper dietary protein and resistance training, rapid weight loss can cause lean tissue loss. InGoodHands integrates high-protein nutrition planning and strength preservation guidelines into your trajectory model to protect muscle mass.
Weight plateaus are natural metabolic adaptation points. Our clinical team evaluates dose titration adequacy, dietary compliance, protein intake, and physical activity to safely adjust your protocol.
Rather than restrictive dieting, our clinical dietitians focus on adequate protein distribution, fiber-rich whole foods, hydration, and moderate calorie deficit strategies tailored to Indian meal patterns.
Patients typically begin seeing early weight reduction (1–3 kg) within the first 4 weeks during the initial low-dose titration phase as gastric emptying slows and appetite decreases.